Progressive Multiple Sclerosis Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Progressive Multiple Sclerosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 1Phase 2

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis (MS) Primary ProgressiveMultiple Sclerosis (MS) Secondary Progressive+2 more
Tr1X, Inc.39 enrolled2 locationsNCT07477639
Recruiting
Phase 2

The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis

Secondary-progressive Multiple Sclerosis (SPMS)
Cairo University46 enrolled1 locationNCT06599307
Recruiting
Phase 4

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Relapsing Multiple SclerosisPrimary Progressive Multiple Sclerosis
Hoffmann-La Roche60 enrolled17 locationsNCT07483450
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Secondary-progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals1,275 enrolled37 locationsNCT07225504
Recruiting

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Multiple SclerosisPrimary Progressive Multiple SclerosisRemitting-Relapsing Multiple Sclerosis+3 more
Heinrich-Heine University, Duesseldorf837 enrolled2 locationsNCT07426991
Recruiting
Phase 2

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

Progressive Multiple Sclerosis
Hoffmann-La Roche360 enrolled16 locationsNCT07282574
Recruiting
Phase 1

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

Progressive Multiple Sclerosis
Autolus Limited18 enrolled1 locationNCT07139743
Recruiting
Not Applicable

Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients

DepressionProgressive Multiple Sclerosis
University of Michigan40 enrolled1 locationNCT07392879
Recruiting
Not Applicable

Functional Outcomes From Diets in Multiple Sclerosis

Relapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
University of Alabama at Birmingham100 enrolled2 locationsNCT05327322
Recruiting
Phase 3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)156 enrolled22 locationsNCT04047628
Recruiting
Phase 1Phase 2

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Progressive Multiple Sclerosis
Novartis Pharmaceuticals28 enrolled17 locationsNCT06675864
Recruiting
Phase 2

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD54 enrolled7 locationsNCT06292923
Recruiting
Phase 1

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Relapsing Remitting Multiple SclerosisPrimary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis
Queen Mary University of London72 enrolled1 locationNCT03783416
Recruiting
Phase 2

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD55 enrolled1 locationNCT06890923
Recruiting

Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis

Multiple Sclerosis (MS)Relapsing-remitting Multiple Sclerosis (RRMS)Secondary-progressive Multiple Sclerosis (SPMS)+1 more
University Hospital, Basel, Switzerland300 enrolled1 locationNCT05177523
Recruiting
Not Applicable

Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis

Progressive Multiple Sclerosis
Neuromed IRCCS40 enrolled1 locationNCT05811013
Recruiting
Phase 2

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Multiple SclerosisProgressive Multiple Sclerosis
Haukeland University Hospital300 enrolled1 locationNCT05740722